NCT03503149

Brief Summary

Molecular Tumor Board at the Center for Personalized Medicine

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
19mo left

Started Mar 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress84%
Mar 2018Mar 2028

Study Start

First participant enrolled

March 1, 2018

Completed
22 days until next milestone

First Submitted

Initial submission to the registry

March 23, 2018

Completed
27 days until next milestone

First Posted

Study publicly available on registry

April 19, 2018

Completed
9.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2028

Last Updated

April 19, 2018

Status Verified

March 1, 2018

Enrollment Period

10 years

First QC Date

March 23, 2018

Last Update Submit

April 18, 2018

Conditions

Advanced Cancer

Outcome Measures

Primary Outcomes (1)

  • Progression-free survival

    Progression-free survival

    6 months

Secondary Outcomes (1)

  • Overall survival

    an average of 1 year

Interventions

no interventionOTHER

observational study

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with advanced stages of cancer

You may qualify if:

  • Given informed consent ("broad consent" of the University Hospital Tübingen)
  • ≥ 18 years of age
  • Clinical indication for a referral to Molecular Tumor Board by the treating physician

You may not qualify if:

  • The MTB assists the referring physician with the interpretation and the use of tumor molecular profiling data for deciding on a therapeutic strategy. Therefore, this board is confined to cancer patients and cannot provide any service for non-cancer patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Tübingen

Tübingen, Baden-Wurttemberg, 72076, Germany

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Tumor tissue, blood tisssue

Study Officials

  • Ghazaleh Tabatabai, Prof

    University Hospital Tübingen

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ghazaleh Tabatabai, Prof

CONTACT

0049707129ghazaleh.tabatabai@med.uni-tuebingen.de

Nisar P Malek, Prof

CONTACT

0049707129ghazaleh.tabatabai@med.uni-tuebingen.de

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
24 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 23, 2018

First Posted

April 19, 2018

Study Start

March 1, 2018

Primary Completion (Estimated)

March 1, 2028

Study Completion (Estimated)

March 1, 2028

Last Updated

April 19, 2018

Record last verified: 2018-03

Locations

DE(1)